Figure S1 from &lt;i&gt;In Vivo&lt;/i&gt; Efficacy of Tesevatinib in &lt;i&gt;EGFR&lt;/i&gt;-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling